The drug Abilify MyCite, developed by Otsuka Pharmaceutical Co. Ltd, was first approved by the FDA in 2002 to treat schizophrenia. The ingestible sensor, made by Proteus Digital health, was approved for marketing in 2012.
The Food and Drug Administration has approved the first drug in the United States with this digital ingestion tracking system, in an unprecedented move to ensure that patients with mental illness take the medicine prescribed for them.
The FDA said in a statement said that the digitally enhanced medication “works by sending a message from the pill’s sensor to a wearable patch.” “Being able to track ingestion of medications prescribed for illness may be useful for some patients.
The wearable patch that comes with the medication “transmits the information to a mobile application so that patients can track the ingestion of the medication on their smart phone. The drug when comes in contact with liquids transmits information to the patch.
Patients can also permit their caregivers and physician to access the information through a web-based portal